Tempus AI, a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the collaboration with Flatiron Health, a leading HealthTech company dedicated to expanding the possibilities of point-of-care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR, through the Molecular Profiling Integration (MPI). This integration will provide oncologists with seamless access to Tempus’ suite of testing options, enhancing their ability to deliver personalised cancer care.
Flatiron’s MPI—a two-way integration between laboratories and OncoEMR—will allow the 4,200 providers at more than 800 community-based cancer care locations across the US in Flatiron’s network to order and receive results from Tempus directly in the OncoEMR workflow. The integration will enable electronic ordering, order tracking, and the receipt of Tempus test results directly within the OncoEMR platform, significantly reducing administrative burden and improving the experience for care providers.
“This collaboration represents a significant step forward in the integration of Tempus’ molecular profiling capabilities into everyday oncology practice,” said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. “By leveraging Flatiron’s Molecular Profiling Integration within OncoEMR, we are enabling oncologists to access our comprehensive genomic tests with greater efficiency and precision, ultimately enhancing patient care and outcomes.”